NASDAQ:NVIV - InVivo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.11 -0.03 (-0.42 %)
(As of 05/22/2018 11:37 AM ET)
Previous Close$7.10
Today's Range$7.00 - $7.33
52-Week Range$6.25 - $96.25
Volume3,506 shs
Average Volume270,538 shs
Market Capitalization$11.83 million
P/E Ratio-0.39
Dividend YieldN/A
Beta2.47

About InVivo Therapeutics (NASDAQ:NVIV)

InVivo Therapeutics logoInVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Debt-to-Equity Ratio0.03
Current Ratio3.20
Quick Ratio3.20

Price-To-Earnings

Trailing P/E Ratio-0.39
Forward P/E Ratio-0.51
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.37 per share
Price / Book0.96

Profitability

EPS (Most Recent Fiscal Year)($18.50)
Net Income$-26,740,000.00
Net MarginsN/A
Return on Equity-194.69%
Return on Assets-144.68%

Miscellaneous

Employees12
Outstanding Shares1,570,000

InVivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is InVivo Therapeutics' stock symbol?

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

When did InVivo Therapeutics' stock split? How did InVivo Therapeutics' stock split work?

Shares of InVivo Therapeutics reverse split on the morning of Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 16th 2018. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 4 shares after the split.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Hldg (NASDAQ:NVIV) released its quarterly earnings results on Monday, March, 12th. The biotechnology company reported ($3.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.00) by $0.75. View InVivo Therapeutics' Earnings History.

When is InVivo Therapeutics' next earnings date?

InVivo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for InVivo Therapeutics.

Who are some of InVivo Therapeutics' key competitors?

Who are InVivo Therapeutics' key executives?

InVivo Therapeutics' management team includes the folowing people:
  • Dr. Richard M. Toselli, Pres, CEO, Director & Chief Medical Officer (Age 60)
  • Mr. Christopher McNulty, CFO & Principal Accounting Officer (Age 41)
  • Mr. Mark D. Perrin, Consultant (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder and Member of Scientific Advisory Board (Age 69)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 69)

Has InVivo Therapeutics been receiving favorable news coverage?

News articles about NVIV stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. InVivo Therapeutics earned a media sentiment score of 0.18 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of InVivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is InVivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $7.11.

How big of a company is InVivo Therapeutics?

InVivo Therapeutics has a market capitalization of $11.83 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis. InVivo Therapeutics employs 12 workers across the globe.

How can I contact InVivo Therapeutics?

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for InVivo Therapeutics (NVIV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  129
MarketBeat's community ratings are surveys of what our community members think about InVivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

InVivo Therapeutics (NASDAQ:NVIV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for InVivo Therapeutics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.002.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$150.00$150.00$150.00
Price Target Upside: N/A8,233.33% upside8,233.33% upside8,233.33% upside

InVivo Therapeutics (NASDAQ:NVIV) Consensus Price Target History

Price Target History for InVivo Therapeutics (NASDAQ:NVIV)

InVivo Therapeutics (NASDAQ:NVIV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/31/2017Raymond JamesDowngradeOutperform ➝ Market PerformN/AView Rating Details
5/5/2017UBSDowngradeStrong-Buy ➝ OutperformN/AView Rating Details
7/21/2016Ladenburg ThalmannInitiated CoverageBuy$581.25N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

InVivo Therapeutics (NASDAQ:NVIV) Earnings History and Estimates Chart

Earnings by Quarter for InVivo Therapeutics (NASDAQ:NVIV)

InVivo Therapeutics (NASDAQ:NVIV) Earnings Estimates

Current Year EPS Consensus Estimate: $-13.88 EPS
Next Year EPS Consensus Estimate: $-11.5 EPS

InVivo Therapeutics (NASDAQ NVIV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
3/12/2018Q4 2017($4.00)($3.25)ViewN/AView Earnings Details
10/30/2017Q3 2017($5.50)($7.00)ViewN/AView Earnings Details
8/8/2017Q2 2017($5.25)($5.00)ViewN/AView Earnings Details
5/4/2017Q1 2017($5.50)($5.00)ViewN/AView Earnings Details
3/10/2017Q4 2016($5.00)($5.25)ViewN/AView Earnings Details
11/4/2016Q3($5.00)($4.50)ViewN/AView Earnings Details
8/4/2016Q2($5.50)($4.50)ViewN/AView Earnings Details
5/6/2016Q1 2016($6.50)($5.00)ViewN/AView Earnings Details
3/4/2016Q4 2015($5.50)($4.75)ViewN/AView Earnings Details
11/4/2015Q3 2015($5.00)($5.50)ViewN/AView Earnings Details
8/5/2015Q2 2015($4.50)($5.25)ViewN/AView Earnings Details
5/7/2015Q1 2015($2.75)($5.50)ViewN/AView Earnings Details
3/11/2015Q4 2014($6.00)($4.00)ViewN/AView Earnings Details
11/5/2014Q3 2014($6.00)($4.00)ViewN/AView Earnings Details
8/6/2014Q2 2014($6.00)($5.00)ViewN/AView Earnings Details
5/12/2014Q1 2014($8.00)($7.00)ViewN/AView Earnings Details
3/17/2014($2.00)($1.50)ViewN/AView Earnings Details
11/7/2013Q3 2013($7.00)($7.00)ViewN/AView Earnings Details
8/7/2013Q2 2013($7.00)($8.00)ViewN/AView Earnings Details
5/9/2013Q1 2013($8.00)($4.00)ViewN/AView Earnings Details
3/13/2013Q4 2012($6.00)($7.00)ViewN/AView Earnings Details
11/14/2012Q3 2012($6.00)($4.00)ViewN/AView Earnings Details
8/14/2012Q2 2012($6.00)($3.75)ViewN/AView Earnings Details
5/15/2012Q1 2012($2.00)($4.50)ViewN/AView Earnings Details
3/15/2012Q4 2011($4.00)($5.00)ViewN/AView Earnings Details
11/15/2011Q3 2011($4.00)($4.00)ViewN/AView Earnings Details
8/11/2011Q2 2011($3.00)($5.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

InVivo Therapeutics (NASDAQ:NVIV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

InVivo Therapeutics (NASDAQ NVIV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.80%
Insider Trading History for InVivo Therapeutics (NASDAQ:NVIV)
Institutional Ownership by Quarter for InVivo Therapeutics (NASDAQ:NVIV)

InVivo Therapeutics (NASDAQ NVIV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2014Francis ReynoldsMajor ShareholderSell50,000$1.20$60,000.00View SEC Filing  
5/5/2014Francis ReynoldsMajor ShareholderSell37,500$1.87$70,125.00View SEC Filing  
4/30/2014Francis ReynoldsMajor ShareholderSell37,500$1.82$68,250.00View SEC Filing  
4/25/2014Francis ReynoldsMajor ShareholderSell50,000$1.52$76,000.00View SEC Filing  
4/21/2014Francis ReynoldsMajor ShareholderSell50,000$1.57$78,500.00View SEC Filing  
4/14/2014Francis ReynoldsMajor ShareholderSell37,500$1.63$61,125.00View SEC Filing  
4/9/2014Francis ReynoldsMajor ShareholderSell37,500$1.60$60,000.00View SEC Filing  
4/4/2014Francis ReynoldsMajor ShareholderSell25,000$1.71$42,750.00View SEC Filing  
4/2/2014Francis ReynoldsMajor ShareholderSell37,500$1.71$64,125.00View SEC Filing  
3/26/2014Francis ReynoldsMajor ShareholderSell47,900$1.80$86,220.00View SEC Filing  
3/21/2014Francis ReynoldsMajor ShareholderSell39,600$2.15$85,140.00View SEC Filing  
3/17/2014Francis ReynoldsMajor ShareholderSell37,500$2.44$91,500.00View SEC Filing  
3/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.33$87,375.00View SEC Filing  
3/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
3/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.49$93,375.00View SEC Filing  
2/28/2014Francis ReynoldsMajor ShareholderSell25,000$2.44$61,000.00View SEC Filing  
2/26/2014Francis ReynoldsMajor ShareholderSell37,500$2.28$85,500.00View SEC Filing  
2/21/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/19/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
2/14/2014Francis ReynoldsMajor ShareholderSell25,000$2.24$56,000.00View SEC Filing  
2/12/2014Francis ReynoldsMajor ShareholderSell37,500$2.25$84,375.00View SEC Filing  
2/7/2014Francis ReynoldsMajor ShareholderSell25,000$2.23$55,750.00View SEC Filing  
2/5/2014Francis ReynoldsMajor ShareholderSell37,500$2.21$82,875.00View SEC Filing  
1/31/2014Francis ReynoldsMajor ShareholderSell25,000$2.17$54,250.00View SEC Filing  
1/29/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/24/2014Francis ReynoldsMajor ShareholderSell25,000$2.25$56,250.00View SEC Filing  
1/21/2014Francis ReynoldsMajor ShareholderSell37,500$2.36$88,500.00View SEC Filing  
1/15/2014Francis ReynoldsMajor ShareholderSell37,500$2.22$83,250.00View SEC Filing  
1/10/2014Francis ReynoldsMajor ShareholderSell48,000$2.41$115,680.00View SEC Filing  
1/6/2014Francis ReynoldsMajor ShareholderSell36,000$2.28$82,080.00View SEC Filing  
12/31/2013Francis ReynoldsMajor ShareholderSell36,000$2.25$81,000.00View SEC Filing  
12/26/2013Francis ReynoldsMajor ShareholderSell36,000$1.99$71,640.00View SEC Filing  
12/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.96$47,040.00View SEC Filing  
12/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
12/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.80$43,200.00View SEC Filing  
12/11/2013Francis ReynoldsMajor ShareholderSell36,000$1.75$63,000.00View SEC Filing  
12/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.59$38,160.00View SEC Filing  
12/4/2013Francis ReynoldsMajor ShareholderSell36,000$1.90$68,400.00View SEC Filing  
11/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.92$46,080.00View SEC Filing  
11/20/2013Francis ReynoldsMajor ShareholderSell36,000$1.95$70,200.00View SEC Filing  
11/13/2013Francis ReynoldsMajor ShareholderSell36,000$1.14$41,040.00View SEC Filing  
11/8/2013Francis ReynoldsMajor ShareholderSell24,000$1.11$26,640.00View SEC Filing  
11/6/2013Francis ReynoldsMajor ShareholderSell36,000$1.16$41,760.00View SEC Filing  
11/1/2013Francis ReynoldsMajor ShareholderSell24,000$1.16$27,840.00View SEC Filing  
10/30/2013Francis ReynoldsMajor ShareholderSell36,000$1.23$44,280.00View SEC Filing  
10/25/2013Francis ReynoldsMajor ShareholderSell24,000$1.35$32,400.00View SEC Filing  
10/22/2013Francis ReynoldsMajor ShareholderSell24,000$1.40$33,600.00View SEC Filing  
10/18/2013Francis ReynoldsMajor ShareholderSell24,000$1.45$34,800.00View SEC Filing  
10/16/2013Francis ReynoldsMajor ShareholderSell36,000$1.49$53,640.00View SEC Filing  
10/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.51$36,240.00View SEC Filing  
10/9/2013Francis ReynoldsMajor ShareholderSell36,000$1.41$50,760.00View SEC Filing  
10/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.41$33,840.00View SEC Filing  
9/20/2013Francis ReynoldsMajor ShareholderSell24,000$1.37$32,880.00View SEC Filing  
9/18/2013Francis ReynoldsMajor ShareholderSell36,000$1.43$51,480.00View SEC Filing  
9/13/2013Francis ReynoldsMajor ShareholderSell24,000$1.50$36,000.00View SEC Filing  
9/11/2013Francis ReynoldsMajor ShareholderSell24,000$1.72$41,280.00View SEC Filing  
9/6/2013Francis ReynoldsMajor ShareholderSell24,000$1.61$38,640.00View SEC Filing  
9/4/2013Francis ReynoldsMajor ShareholderSell24,000$1.36$32,640.00View SEC Filing  
9/3/2013Sean F MoranCFOBuy20,000$1.02$20,400.00View SEC Filing  
8/30/2013Francis ReynoldsMajor ShareholderSell9,200$1.55$14,260.00View SEC Filing  
8/30/2013Sean F MoranCFOBuy40,000$1.30$52,000.00View SEC Filing  
8/28/2013Francis ReynoldsMajor ShareholderSell12,600$3.24$40,824.00View SEC Filing  
8/23/2013Francis ReynoldsMajor ShareholderSell21,300$4.07$86,691.00View SEC Filing  
8/21/2013Francis ReynoldsCEOSell36,000$4.12$148,320.00View SEC Filing  
8/16/2013Francis ReynoldsCEOSell24,000$4.24$101,760.00View SEC Filing  
8/14/2013Francis ReynoldsCEOSell36,000$4.34$156,240.00View SEC Filing  
8/9/2013Francis ReynoldsCEOSell24,000$4.42$106,080.00View SEC Filing  
8/7/2013Francis ReynoldsCEOSell36,000$4.46$160,560.00View SEC Filing  
8/2/2013Francis ReynoldsCEOSell24,000$4.57$109,680.00View SEC Filing  
7/30/2013Francis ReynoldsCEOSell24,000$5.11$122,640.00View SEC Filing  
7/26/2013Francis ReynoldsCEOSell24,000$5.29$126,960.00View SEC Filing  
7/24/2013Francis ReynoldsCEOSell36,000$5.72$205,920.00View SEC Filing  
7/19/2013Francis ReynoldsCEOSell24,000$5.27$126,480.00View SEC Filing  
7/17/2013Francis ReynoldsCEOSell36,000$5.12$184,320.00View SEC Filing  
7/12/2013Francis ReynoldsCEOSell24,000$4.43$106,320.00View SEC Filing  
7/10/2013Francis ReynoldsCEOSell36,000$3.97$142,920.00View SEC Filing  
7/5/2013Francis ReynoldsCEOSell12,000$4.00$48,000.00View SEC Filing  
7/3/2013Francis ReynoldsCEOSell36,000$4.08$146,880.00View SEC Filing  
6/28/2013Francis ReynoldsCEOSell24,000$4.22$101,280.00View SEC Filing  
6/26/2013Francis ReynoldsCEOSell36,000$3.87$139,320.00View SEC Filing  
6/21/2013Francis ReynoldsCEOSell24,000$3.78$90,720.00View SEC Filing  
6/19/2013Francis ReynoldsCEOSell36,000$3.89$140,040.00View SEC Filing  
6/14/2013Francis ReynoldsCEOSell24,000$3.84$92,160.00View SEC Filing  
6/12/2013Francis ReynoldsCEOSell12,750$4.34$55,335.00View SEC Filing  
6/7/2013Francis ReynoldsCEOSell8,500$4.02$34,170.00View SEC Filing  
6/5/2013Francis ReynoldsCEOSell12,750$3.75$47,812.50View SEC Filing  
6/5/2013Robert LangerMajor ShareholderSell7,500$3.73$27,975.00View SEC Filing  
5/31/2013Francis ReynoldsCEOSell8,500$3.32$28,220.00View SEC Filing  
5/31/2013Robert LangerMajor ShareholderSell7,500$3.31$24,825.00View SEC Filing  
5/29/2013Francis ReynoldsCEOSell8,500$3.13$26,605.00View SEC Filing  
5/28/2013Robert LangerMajor ShareholderSell7,500$2.97$22,275.00View SEC Filing  
5/24/2013Francis ReynoldsCEOSell8,500$2.95$25,075.00View SEC Filing  
5/22/2013Robert LangerMajor ShareholderSell7,500$2.88$21,600.00View SEC Filing  
5/21/2013Francis ReynoldsCEOSell12,750$2.88$36,720.00View SEC Filing  
5/17/2013Francis ReynoldsCEOSell8,500$2.87$24,395.00View SEC Filing  
5/17/2013Robert LangerMajor ShareholderSell7,500$2.85$21,375.00View SEC Filing  
5/15/2013Francis ReynoldsCEOSell12,750$2.89$36,847.50View SEC Filing  
5/14/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
5/10/2013Francis ReynoldsCEOSell8,500$2.92$24,820.00View SEC Filing  
5/9/2013Robert LangerMajor ShareholderSell7,500$2.91$21,825.00View SEC Filing  
4/12/2013Francis ReynoldsCEOSell8,500$3.16$26,860.00View SEC Filing  
2/5/2013Francis ReynoldsCEOSell12,750$2.03$25,882.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

InVivo Therapeutics (NASDAQ NVIV) News Headlines

Source:
DateHeadline
Heads Up Trading: How Market Awarenes Helped To Make A $24k TradeHeads Up Trading: How Market Awarenes Helped To Make A $24k Trade
www.benzinga.com - May 12 at 5:44 PM
Brokerages Anticipate InVivo Therapeutics Hldg (NVIV) to Post ($3.25) EPSBrokerages Anticipate InVivo Therapeutics Hldg (NVIV) to Post ($3.25) EPS
www.americanbankingnews.com - May 10 at 5:37 AM
InVivo Therapeutics (NVIV) Lowered to Strong Sell at ValuEngineInVivo Therapeutics (NVIV) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - May 8 at 11:26 PM
InVivo: 1Q Earnings SnapshotInVivo: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:24 AM
InVivo Therapeutics Reports 2018 First Quarter Financial ResultsInVivo Therapeutics Reports 2018 First Quarter Financial Results
finance.yahoo.com - May 7 at 5:33 PM
 Analysts Anticipate InVivo Therapeutics Hldg (NVIV) to Announce -$3.25 Earnings Per Share Analysts Anticipate InVivo Therapeutics Hldg (NVIV) to Announce -$3.25 Earnings Per Share
www.americanbankingnews.com - May 5 at 11:13 AM
InVivo Therapeutics (NVIV) Downgraded by ValuEngineInVivo Therapeutics (NVIV) Downgraded by ValuEngine
www.americanbankingnews.com - May 2 at 11:38 PM
Why InVivo Therapeutics Shares Are SkyrocketingWhy InVivo Therapeutics Shares Are Skyrocketing
www.msn.com - May 2 at 5:31 PM
Zacks: InVivo Therapeutics Hldg (NVIV) Given $118.75 Consensus Price Target by AnalystsZacks: InVivo Therapeutics Hldg (NVIV) Given $118.75 Consensus Price Target by Analysts
www.americanbankingnews.com - April 25 at 1:26 PM
BRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln SharesBRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln Shares
www.reuters.com - April 25 at 8:25 AM
InVivo Therapeutics (NVIV) Upgraded at ValuEngineInVivo Therapeutics (NVIV) Upgraded at ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
Zacks: Brokerages Anticipate InVivo Therapeutics Hldg (NVIV) Will Post Earnings of -$3.25 Per ShareZacks: Brokerages Anticipate InVivo Therapeutics Hldg (NVIV) Will Post Earnings of -$3.25 Per Share
www.americanbankingnews.com - April 18 at 11:14 AM
Today’s Research Reports on Stocks to Watch: vTv Therapeutics and InVivo TherapeuticsToday’s Research Reports on Stocks to Watch: vTv Therapeutics and InVivo Therapeutics
finance.yahoo.com - April 18 at 8:23 AM
InVivo to reverse split shares 1:25 April 16InVivo to reverse split shares 1:25 April 16
seekingalpha.com - April 10 at 8:37 AM
BRIEF-Invivo Therapeutics Announces Reverse Stock SplitBRIEF-Invivo Therapeutics Announces Reverse Stock Split
www.reuters.com - April 10 at 8:37 AM
InVivo Therapeutics Stock Scheduled to Reverse Split on Tuesday, April 17th (NVIV)InVivo Therapeutics Stock Scheduled to Reverse Split on Tuesday, April 17th (NVIV)
www.americanbankingnews.com - April 9 at 1:27 PM
InVivo Therapeutics Provides Business UpdateInVivo Therapeutics Provides Business Update
finance.yahoo.com - April 9 at 8:28 AM
 InVivo Therapeutics Hldg (NVIV) Given Consensus Recommendation of "Buy" by Brokerages InVivo Therapeutics Hldg (NVIV) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 11:12 PM
 Brokerages Anticipate InVivo Therapeutics Hldg (NVIV) to Post -$0.13 EPS Brokerages Anticipate InVivo Therapeutics Hldg (NVIV) to Post -$0.13 EPS
www.americanbankingnews.com - April 1 at 11:22 AM
Critical Review: InVivo Therapeutics (NVIV) and Accelerate Diagnostics (AXDX)Critical Review: InVivo Therapeutics (NVIV) and Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - March 24 at 7:19 PM
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings - Business Wire (press release)InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings - Business Wire (press release)
www.businesswire.com - March 19 at 8:29 AM
Invivo Therapeutics (NVIV) Reports Top-Line Results from Contemporary Thoracic SCI Registry Study - StreetInsider.comInvivo Therapeutics (NVIV) Reports Top-Line Results from Contemporary Thoracic SCI Registry Study - StreetInsider.com
www.streetinsider.com - March 19 at 8:29 AM
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) FindingsInVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings
finance.yahoo.com - March 19 at 8:29 AM
 Analysts Expect Invivo Therapeutics Holdings Corp (NVIV) to Post -$0.17 Earnings Per Share Analysts Expect Invivo Therapeutics Holdings Corp (NVIV) to Post -$0.17 Earnings Per Share
www.americanbankingnews.com - March 15 at 1:18 PM
InVivo Therapeutics Reports 2017 Year-end Financial Results - Business Wire (press release)InVivo Therapeutics Reports 2017 Year-end Financial Results - Business Wire (press release)
www.businesswire.com - March 14 at 8:45 AM
Invivo Therapeutics (NVIV) Releases Quarterly  Earnings Results, Beats Estimates By $0.03 EPSInvivo Therapeutics (NVIV) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 13 at 7:14 AM
Invivo Therapeutics (NVIV) Announces FDA Approval for Trial of Neuro-Spinal ScaffoldInvivo Therapeutics (NVIV) Announces FDA Approval for Trial of Neuro-Spinal Scaffold
www.streetinsider.com - March 9 at 6:42 PM
Is It Time To Buy InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)?Is It Time To Buy InVivo Therapeutics Holdings Corp (NASDAQ:NVIV)?
finance.yahoo.com - March 9 at 6:42 PM
Today’s Research Reports on Stocks to Watch: Johnson & Johnson and InVivo TherapeuticsToday’s Research Reports on Stocks to Watch: Johnson & Johnson and InVivo Therapeutics
finance.yahoo.com - March 9 at 8:27 AM
BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™
www.reuters.com - March 8 at 6:30 PM
Invivo Therapeutics (NVIV) Announces FDA Approval for Trial of Neuro-Spinal Scaffold - StreetInsider.comInvivo Therapeutics (NVIV) Announces FDA Approval for Trial of Neuro-Spinal Scaffold - StreetInsider.com
www.streetinsider.com - March 8 at 8:31 AM
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord InjuryInVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury
finance.yahoo.com - March 8 at 8:31 AM
Invivo Therapeutics (NVIV) and Quidel (QDEL) Head-To-Head SurveyInvivo Therapeutics (NVIV) and Quidel (QDEL) Head-To-Head Survey
www.americanbankingnews.com - March 7 at 3:28 PM
Critical Survey: Invivo Therapeutics (NVIV) and Bruker (BRKR)Critical Survey: Invivo Therapeutics (NVIV) and Bruker (BRKR)
www.americanbankingnews.com - March 7 at 1:16 AM
Comparing Invivo Therapeutics (NVIV) & Edwards Lifesciences (EW)Comparing Invivo Therapeutics (NVIV) & Edwards Lifesciences (EW)
www.americanbankingnews.com - March 5 at 7:12 PM
Invivo Therapeutics (NVIV) to Release Quarterly Earnings on ThursdayInvivo Therapeutics (NVIV) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - March 1 at 1:12 AM
Zacks: Analysts Anticipate Invivo Therapeutics Holdings Corp (NVIV) to Post -$0.16 Earnings Per ShareZacks: Analysts Anticipate Invivo Therapeutics Holdings Corp (NVIV) to Post -$0.16 Earnings Per Share
www.americanbankingnews.com - February 26 at 10:48 AM
 Brokerages Anticipate Invivo Therapeutics Holdings Corp (NVIV) Will Announce Earnings of -$0.16 Per Share Brokerages Anticipate Invivo Therapeutics Holdings Corp (NVIV) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 9 at 3:48 PM
Head to Head Survey: PerkinElmer (PKI) & Invivo Therapeutics (NVIV)Head to Head Survey: PerkinElmer (PKI) & Invivo Therapeutics (NVIV)
www.americanbankingnews.com - February 6 at 3:04 AM
Form 8-K INVIVO THERAPEUTICS HOLD For: Feb 02Form 8-K INVIVO THERAPEUTICS HOLD For: Feb 02
www.streetinsider.com - February 5 at 9:48 AM
InVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive OfficerInVivo Therapeutics Announces Appointment of Richard Toselli, M.D., as President and Chief Executive Officer
finance.yahoo.com - February 5 at 9:48 AM
Blog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park CapitalBlog Exposure - InVivo Therapeutics Signs Share Repurchase Agreement with Lincoln Park Capital
finance.yahoo.com - January 29 at 10:05 AM
Short Interest in Invivo Therapeutics Holdings Corp (NVIV) Decreases By 22.9%Short Interest in Invivo Therapeutics Holdings Corp (NVIV) Decreases By 22.9%
www.americanbankingnews.com - January 29 at 1:40 AM
Invivo Therapeutics (NVIV) Reports Common Share Purchase Agreement for up to $15M with Lincoln Park CapitalInvivo Therapeutics (NVIV) Reports Common Share Purchase Agreement for up to $15M with Lincoln Park Capital
www.streetinsider.com - January 27 at 10:10 AM
BRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park CapitalBRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park Capital
www.reuters.com - January 26 at 9:50 AM
InVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park CapitalInVivo Therapeutics Announces Purchase Agreement for up to $15 Million with Lincoln Park Capital
finance.yahoo.com - January 26 at 9:50 AM
Head to Head Analysis: Invivo Therapeutics (NVIV) & Hologic (HOLX)Head to Head Analysis: Invivo Therapeutics (NVIV) & Hologic (HOLX)
www.americanbankingnews.com - January 7 at 11:26 PM
-$0.16 EPS Expected for Invivo Therapeutics Holdings Corp (NVIV) This Quarter-$0.16 EPS Expected for Invivo Therapeutics Holdings Corp (NVIV) This Quarter
www.americanbankingnews.com - January 6 at 1:34 PM
Invivo Therapeutics (NVIV) & IRIDEX (IRIX) Head-To-Head ReviewInvivo Therapeutics (NVIV) & IRIDEX (IRIX) Head-To-Head Review
www.americanbankingnews.com - January 6 at 9:46 AM
Analyzing LeMaitre Vascular (LMAT) & Invivo Therapeutics (NVIV)Analyzing LeMaitre Vascular (LMAT) & Invivo Therapeutics (NVIV)
www.americanbankingnews.com - January 5 at 5:04 AM

SEC Filings

InVivo Therapeutics (NASDAQ:NVIV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

InVivo Therapeutics (NASDAQ:NVIV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

InVivo Therapeutics (NASDAQ NVIV) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.